share_log

Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of...

Benzinga ·  Oct 30 06:20

Scilex Announced It Had A Successful End Of Phase II Meeting With The FDA Leading To An Agreed Path Forward To NDA Upon Completion Of Phase III Trials For Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4% For The Treatment Of Chronic Neck Pain Associated With Muscle Spasms

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment